Sanofi India Ltd.
Snapshot View

6506.90 -27.90 ▼-0.4%

27 May 2022, 04:01:00 PM
Volume: 405

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.sanofiindialtd.com
Market Cap 15,012.40 Cr.
Enterprise Value(EV) 13,462.10 Cr. 2021-12
Financial Indicators
Earnings per share (EPS) 450.23 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 14.48 Trailing Twelve Months Ending 2022-03
Industry PE 28.15 Trailing Twelve Months Ending 2022-03
Book Value / Share 1,043.80 Trailing Twelve Months Ending 2022-03
Price to Book Value 6.24 Calculated using Price: 6,518.45
Dividend Yield 7.52 Period Ending 2021-12
No. of Shares Subscribed 2.30 Cr. 23,030,622 Shares
FaceValue 10
Company Profile

Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.

Business area of the company

The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Products

Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).

Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)

Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,
Triomega)

Milestones

  • 2013: Sanofi India launches Combiflam Plus.
  • 2013: Sanofi ties up with IDF, PHFI to fight against diabetes among children in India.
  • 2013: Sanofi India inks pact with Suzlon Energy for renewable energy.
  • 2014: Sanofi India - Diabetic Teen from Pune achieves unique feat.
  • 2014: Sanofi partners with Emcure Pharmaceuticals for marketing and distribution of its oncology portfolio in India.
  • 2015: Sanofi delivers 4 lakh Shan5 vaccine doses to Gwalior and Jabalpur to support the immunization of children from five pediatric diseases.
  • 2016: Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research.
  • 2018: Sanofi receives positive CHMP opinion for dengue vaccine.
  • 2018: Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure.
  • 2019: Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care.
  • 2020: Sanofi Completes Acquisition of Synthorx, Inc.
  • 2020: Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine.
  • 2020: Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.43%
1 Week
-1.15%
1 Month
-6.76%
3 Month
-9.89%
6 Month
-20.90%
1 Year
-16.00%
2 Year
-16.17%
5 Year
+62.21%
10 Year
+213.25%
9 years 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12 2021-12
Return on Equity (%) 20.97 18.70 20.68 17.43 16.87 18.18 18.07 21.39 44.65
Return on Capital Employed (%) 30.75 26.47 30.96 27.51 26.38 28.76 25.75 29.77 57.98
Return on Assets (%) 15.11 12.84 13.88 12.30 9.50 8.37 8.28 9.24 17.74

Balance Sheet View Details

Particulars 10 years 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2014-12 Rs. Cr. 2015-12 Rs. Cr. 2016-12 Rs. Cr. 2017-12 Rs. Cr. 2018-12 Rs. Cr. 2019-12 Rs. Cr. 2020-12 Rs. Cr. 2021-12 Rs. Cr.
Shh. Funds 1,204 1,347 1,486 1,627 1,883 2,026 2,219 2,442 2,119 2,226
Non Curr. Liab. 41 63 86 161 156 1,335 1,357 1,124 1,280 1,039
Curr. Liab. 387 469 656 617 502 962 1,193 1,674 1,694 2,291
Minority Int.
Equity & Liab. 1,631 1,878 2,228 2,405 2,541 4,324 4,769 5,240 5,093 5,555
Non Curr. Assets 803 931 965 1,161 966 2,519 2,608 2,141 2,253 1,876
Curr. Assets 829 947 1,263 1,244 1,575 1,805 2,162 3,099 2,841 3,679
Misc. Exp. not W/O
Total Assets 1,631 1,878 2,228 2,405 2,541 4,324 4,769 5,240 5,093 5,555

Profit Loss View Details

Particulars 10 years 2013-12 Rs. Cr. 2014-12 Rs. Cr. 2015-12 Rs. Cr. 2016-12 Rs. Cr. 2017-12 Rs. Cr. 2018-12 Rs. Cr. 2019-12 Rs. Cr. 2020-12 Rs. Cr. 2021-12 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 1,809 1,977 2,193 2,367 2,464 2,771 3,071 2,902 2,957 2,939
Other Income 58 64 51 66 81 90 94 90 75 73
Total Income 1,867 2,042 2,245 2,433 2,544 2,861 3,165 2,992 3,031 3,011
Total Expenditure -1,411 -1,639 -1,734 -1,832 -1,926 -2,148 -2,405 -2,189 -2,194 -2,171
PBIDT 456 403 511 602 618 713 759 803 837 840
Interest 0 0 0 -2 -1 -1 0 -2 -2 -2
Depreciation -92 -97 -113 -119 -102 -103 -100 -82 -67 -57
Taxation -123 -109 -159 -176 -189 -229 -186 -200 -313 -352
Exceptional Items 25 67 84 -59 -42 489 607
PAT 265 264 322 304 326 381 414 478 944 1,037
Adjusted EPS 115 114 140 132 142 165 180 208 411 451

Cash Flow View Details

Particulars 10 years 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2014-12 Rs. Cr. 2015-12 Rs. Cr. 2016-12 Rs. Cr. 2017-12 Rs. Cr. 2018-12 Rs. Cr. 2019-12 Rs. Cr. 2020-12 Rs. Cr. 2021-12 Rs. Cr.
Cash Fr. Operatn. 290 273 265 213 322 435 374 412 611 559
Cash Fr. Inv. -5 -335 61 36 -155 -79 -73 66 276 631
Cash Fr. Finan. -90 -105 -122 -147 -180 -188 -197 -183 -810 -849
Net Change 195 -168 205 102 -13 168 104 295 78 341
Cash & Cash Eqvt 429 261 466 568 554 722 825 1,120 1,197 1,538

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 60.40 60.40 60.40 60.40 60.40 60.40 60.40 60.40 60.40
Public 39.60 39.60 39.60 39.60 39.60 39.60 39.60 39.60 39.60
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 26 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the Notice to shareholders of the Company published today in newspapers Business Standard and Sakal..
Wed, 25 May 2022
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s) details of which are enclosed.
Mon, 23 May 2022
Completion Of Dispatchment Of Postal Ballot
Further to our letter dated 13th May 2022 this is to inform that the Company is seeking approval of Members of the Company through an Ordinary Resolution for appointment of Mr. Rodolfo Hrosz as Additional Director and Managing Director of the Company by way of Postal Ballot as detailed in the Postal Ballot Notice dated 26th April 2022.

Please find enclosed copy of the Postal Ballot Notice together with the Explanatory Statement for your record.

The Company has today 23rd May 2022 sent an e-mail through Central Depository Services (India) Limited CDSL along with the Login ID and password to the Members for e-voting who have registered their e-mail ids with Depository Participant(s) or with the Company.

The voting period will commence from Tuesday 24th May 2022 IST at 9.00 a.m. and will end on Wednesday 22nd June 2022 IST at 5.00 p.m. You are requested to kindly take the above information on record

Technical Scans View Details

Fri, 27 May 2022
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 6 Months High Decrease 6 Months
Thu, 26 May 2022
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 216,539.98 902.50 +0.2%
Divi's Laboratories Ltd. 93,297.61 3,514.45 +1.9%
Cipla Ltd. 77,954.36 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. 73,094.23 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. 55,313.96 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. 49,744.83 2,939.85 +1.3%
Gland Pharma Ltd. 47,677.82 2,897.00 +1.5%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.60 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2022-03 31.51 3,514.45 +1.9%
Cipla Ltd. Consolidated 2022-03 30.97 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.49 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 52.40 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 64.02 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2022-03 39.35 2,897.00 +1.5%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.19 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2022-03 7.95 3,514.45 +1.9%
Cipla Ltd. Consolidated 2022-03 3.74 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.80 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 9.81 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8.36 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2022-03 6.66 2,897.00 +1.5%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 0.10 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,897.00 +1.5%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 14.13 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,897.00 +1.5%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 14.13 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,897.00 +1.5%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 19,159.59 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,897.00 +1.5%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 2,401.30 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,897.00 +1.5%